Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
Date:2/27/2013

t assume any responsibility for updating any forward-looking statements. VIROHARMA INCORPORATEDSelected Financial Information(unaudited)Consolidated Statements of Operations:Three months endedYear ended(in thousands, except per share data)

December 31,December 31,2012201120122011Revenues:Net product sales

$
,490$
45,575$
427,933$
544,374Costs and Expenses:Cost of sales (excluding amortization

 of product rights)

26,82719,683108,54779,976Research and development

19,14212,70767,70966,477Selling, general and administrative

50,97836,022174,315127,775Intangible amortization

8,8577,77435,30131,035Impairment loss

---8,495Other operating expenses

2,710948,7188,488Total costs and expenses

108,51476,280394,590322,246Operating income (loss) 

(2,024)69,29533,343222,128Interest income

188140594655Interest expense

(3,599)(3,475)(14,093)(12,640)Other income (loss), net

3,941(2,563)(823)(2,136)Income (loss) before income tax expense

(1,494)63,39719,021208,007Income tax expense 

2,48910,21913,41067,348Net income (loss) 

$
(3,983)$
53,178$
5,611$
40,659Basic net income (loss) per share

$
(0.06)$
.75$
.08$
.89Diluted net income (loss) per share

$
(0.06)$
.65$
.08$
.68Shares used in computing net income  per share:Basic

65,38570,49968,21474,517Diluted

65,38584,49371,76488,076VIROPHARMA INCORPORATEDSelected Financial Information(unaudited)Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted Net IncomeAn itemized reconciliation between net income (loss) and adjusted net income on a non-GAAP basis is as follows:(in thousands)

Three months endedTwelve months endedDecember 31,December 31,2012201120122011GAAP net  income (loss)

$
(3,983)$
53,178$
5,611$
40,659Adjustments:Non-cash interest expe
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
2. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
3. ViroPharma To Participate In The JMP Securities Healthcare Conference
4. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
5. ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
6. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
7. ViroPharma to Present at the Stifel Nicolaus 2012 Healthcare Conference
8. ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
9. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
10. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
11. ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)...   Clementia Pharmaceuticals, Inc. today announced ... part (Part B) of its natural history study ... rare, severely disabling congenital myopathy characterized by painful, ... result in the formation of new, abnormal (heterotopic) ... The multi-center, non-interventional, two-part longitudinal study is ...
(Date:5/28/2015)... 2015 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), ... that its President and Chief Executive Officer, David ... Invitational Investor Conference being held at the Luxe ... on June 1-3, 2015. Mr. Hansen ... significant progress made in the last year and plans ...
(Date:5/28/2015)... , May 28, 2015  Caris Life Sciences®, ... promise of precision medicine, today announced the presentation ... demonstrate the utility of Caris Molecular Intelligence®, the ... mechanisms of drug resistance and pathway alterations in ... in poster sessions at the annual meeting of ...
Breaking Medicine Technology:Clementia Advances Natural History Study of Patients with Fibrodysplasia Ossificans Progressiva 2Clementia Advances Natural History Study of Patients with Fibrodysplasia Ossificans Progressiva 3MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT 2MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT 3MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT 4Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies 2Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies 3Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies 4Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies 5
... estimate that nearly one-third of cases of melanoma ... diagnosed in women during their childbearing years. Since many women ... with the fact that melanoma is the most common form ... could be faced with developing melanoma before or during pregnancy.At ...
... Up To $55 Million in Near Term Payments ... today announced that the company has entered into ... European rights to develop and commercialize the investigational ... syndrome with constipation (IBS-C) and other gastrointestinal conditions. ...
Cached Medicine Technology:Melanoma and Pregnancy: What Every Woman Needs to Know About the Risks, Prognosis 2Melanoma and Pregnancy: What Every Woman Needs to Know About the Risks, Prognosis 3Melanoma and Pregnancy: What Every Woman Needs to Know About the Risks, Prognosis 4Melanoma and Pregnancy: What Every Woman Needs to Know About the Risks, Prognosis 5Ironwood Announces Linaclotide European Licensing Agreement with Almirall 2Ironwood Announces Linaclotide European Licensing Agreement with Almirall 3
(Date:5/28/2015)... Dallas, TX (PRWEB) May 28, 2015 ... 2015” provides comprehensive information on the therapeutic development ... intermittent muscle contractions causing abnormal, often repetitive, movements, ... children of all ages and backgrounds. The report ... MOAs to produce first-in-class and best-in-class products. Complete ...
(Date:5/28/2015)... Dallas urologist Mark Allen, MD ... patient education website NORTHTEXASUROLOGIST.COM developed by ... readily access current educational information on various urological ... incontinence, prostate cancer treatment, robotic surgery and female ... to educate patients on urological conditions and treatments, ...
(Date:5/28/2015)... Sunshine Coast Health Center, one of Canada's top-rated ... http://www.sunshinecoasthealthcentre.ca , is proud to announce a new ... Ontario, community. The company has a new office ... location information for Toronto residents. , "While Powell ... that addiction impacts family and friends," explained Daniel ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 JJ Mowder-Tinney, PT, ... of the New York Physical Therapy Association (NYPTA) by the ... an active member of the NYPTA. At the National ... the Neurology Section Research Committee and an abstract reviewer for ... she has been a member of the Program committee since ...
(Date:5/27/2015)... Throughout the past few months, Push to Walk has acted ... reliability of the Shaw Gait Assessment in comparison to the ... the Department of Physical Therapy at Seton Hall University is ... Assessment is a free online tool, where the GaitRite is ... the gold standard in providing information about how someone walks. ...
Breaking Medicine News(10 mins):Health News:Dystonia Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Dystonia Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Dystonia Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Mark Allen MD, Dallas Urologist, Launches Updated Patient Education Website With a Focus on Prostate Cancer and Erectile Dysfunction Treatment 2Health News:Toronto Alcohol Treatment and Drug Rehab Local Information Page Updated, Announces Sunshine Coast Health Center 2Health News:Toronto Alcohol Treatment and Drug Rehab Local Information Page Updated, Announces Sunshine Coast Health Center 3Health News:Push to Walk Partners with Seton Hall University for Study 2
... deaths in Michigan remained steady in 2011, as 141 workers ... to an annual report from Michigan State University. The ... agriculture industry had the second most at 22, according to ... The program administered by MSU,s Division of ...
... role in wound healing and embryonic development. The ... of cells, has also been linked to pathological ... processes, fibronectin fibers are believed to experience mechanical ... structural modifications that change their biological activity. While ...
... the treatment and survival rate of elderly patients diagnosed ... awarded almost 2million by the National Institute of Health ... effectively as younger women. Professor Malcolm Reed and ... University of Sheffield are leading the ground-breaking programme - ...
... dose of 10 milligrams (mg) daily of S-equol delivered via ... effective as a standard dose of soy isoflavones at reducing ... relieving muscle and joint pain, according to a peer-reviewed study ... of Women,s Health , available now as a Fast Track ...
... from the Bellvitge Biomedical Research Institute (IDIBELL) have shown ... initiation, progression and metastasis of tumours in human breast ... cells. The results of this study have been advanced ... Research . RANK signalling pathway , ...
... PHILADELPHIA - A cellular protein called HDAC6, newly characterized ... may provide a novel target for treating and preventing ... (PTSD), according to research from the Perelman School of ... are natural steroids secreted by the body during stress. ...
Cached Medicine News:Health News:On-the-job deaths steady in Michigan; Number of burn injuries underreported 2Health News:Molecular probes identify changes in fibronectin that may lead to disease 2Health News:Molecular probes identify changes in fibronectin that may lead to disease 3Health News:Bridging the gap in treatment for older women with breast cancer 2Health News:Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women 2Health News:Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women 3Health News:Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women 4Health News:Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women 5Health News:Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women 6Health News:RANK protein promotes the initiation, progression and metastasis of human breast cancer 2Health News:Gatekeeper of brain steroid signals boosts emotional resilience to stress 2Health News:Gatekeeper of brain steroid signals boosts emotional resilience to stress 3
Comfortable 3M hypoallergenic medical foam adhesive. Extra adhesive bandages for eye shield sets. 25 packages of 4 each....
Used with eye shield to cushion the eye. Eliminates need for taping shield. No sticky residue. Package 50 per box. White only....
Includes one aluminum Fox eye shield and one eye Garter shield cover. Packaged 50 per box. White only....
Adult size. Clear plastic. Accommodates either eye. Packaged 12 per box. Available in either adult or pediatric size....
Medicine Products: